Hai Yan

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Identification of microbial DNA in human cancer
    Christopher G Duncan
    Preston Robert Tisch Brain Tumor Center, Pediatric Brain Tumor Foundation Institute, Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    BMC Med Genomics 2:22. 2009
  2. ncbi Mutant metabolic enzymes are at the origin of gliomas
    Hai Yan
    The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, North Carolina, USA
    Cancer Res 69:9157-9. 2009
  3. ncbi Allelic variations in gene expression
    Hai Yan
    Duke University Medical Center, Department of Pathology, Durham, North Carolina 27710, USA
    Curr Opin Oncol 16:39-43. 2004
  4. ncbi Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
    Zachary J Reitman
    The Preston Robert Tisch Brain Tumor Center at Duke, Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 108:3270-5. 2011
  5. ncbi HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea
    Genglin Jin
    Department of Pathology, Pediatric Brain Tumor Foundation Institute and Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neuro Oncol 12:956-66. 2010
  6. ncbi OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas
    David C Adamson
    Department of Surgery, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Veterans Affairs Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 70:181-91. 2010
  7. ncbi 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations
    Genglin Jin
    The Preston Robert Tisch Brain Tumor Center at Duke, Pediatric Brain Tumor Foundation Institute, and Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 6:e16812. 2011
  8. ncbi Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes
    Christopher G Duncan
    The Preston Robert Tisch Brain Tumor Center, The Pediatric Brain Tumor Foundation, The Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Oncotarget 1:265-77. 2010
  9. ncbi Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism
    Zachary J Reitman
    Department of Pathology, The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Natl Cancer Inst 102:932-41. 2010
  10. ncbi Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress
    Zheming Lu
    Department of Pathology, The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 69:9105-11. 2009

Collaborators

Detail Information

Publications28

  1. ncbi Identification of microbial DNA in human cancer
    Christopher G Duncan
    Preston Robert Tisch Brain Tumor Center, Pediatric Brain Tumor Foundation Institute, Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    BMC Med Genomics 2:22. 2009
    ..CONCLUSION: DK-MICROBE can identify previously unknown infectious agents in human tumors, and is now available for further applications for the identification of pathogen DNA in human cancer and other diseases...
  2. ncbi Mutant metabolic enzymes are at the origin of gliomas
    Hai Yan
    The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, North Carolina, USA
    Cancer Res 69:9157-9. 2009
    ..IDH1 and IDH2 mutations define a specific subtype of gliomas and may have significant utility for the diagnosis, prognosis, and treatment of patients with these tumors...
  3. ncbi Allelic variations in gene expression
    Hai Yan
    Duke University Medical Center, Department of Pathology, Durham, North Carolina 27710, USA
    Curr Opin Oncol 16:39-43. 2004
    ..Thus, it has been hypothesized that the study of natural differential expression presenting within and among populations may enhance understanding of human phenotypic variation...
  4. ncbi Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
    Zachary J Reitman
    The Preston Robert Tisch Brain Tumor Center at Duke, Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 108:3270-5. 2011
    ..NAAG also was significantly lower in human glioma tissues containing IDH mutations than in gliomas without such mutations. These metabolic changes provide clues to the pathogenesis of tumors associated with IDH gene mutations...
  5. ncbi HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea
    Genglin Jin
    Department of Pathology, Pediatric Brain Tumor Foundation Institute and Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neuro Oncol 12:956-66. 2010
    ..In summary, HDMX exhibits bona fide oncogenic properties and offers a promising molecular target for GBM therapeutic intervention...
  6. ncbi OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas
    David C Adamson
    Department of Surgery, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Veterans Affairs Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 70:181-91. 2010
    ..Mechanistic investigations revealed upregulation of MYC as a potential mechanism whereby OTX2 promotes tumor progression. Our findings define OTX2 as an important oncogenic driver in medulloblastoma...
  7. ncbi 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations
    Genglin Jin
    The Preston Robert Tisch Brain Tumor Center at Duke, Pediatric Brain Tumor Foundation Institute, and Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 6:e16812. 2011
    ..Genetic evidence indicates that these mutations share a common gain of function, but it is unclear whether the shared function is dominant negative activity, neomorphic production of (R)-2-hydroxyglutarate (2HG), or both...
  8. ncbi Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes
    Christopher G Duncan
    The Preston Robert Tisch Brain Tumor Center, The Pediatric Brain Tumor Foundation, The Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Oncotarget 1:265-77. 2010
    ..Our multifaceted genomic evaluation of glioblastoma establishes ERRFI1 as a potential candidate tumor suppressor gene and TACC3 as a potential oncogene, and provides insight on targets for oncogenic pathway-based therapy...
  9. ncbi Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism
    Zachary J Reitman
    Department of Pathology, The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Natl Cancer Inst 102:932-41. 2010
    ..Study of alterations in these metabolic enzymes may provide insights into the metabolism of cancer cells and uncover novel avenues for development of anticancer therapeutics...
  10. ncbi Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress
    Zheming Lu
    Department of Pathology, The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 69:9105-11. 2009
    ....
  11. ncbi IDH1 and IDH2 mutations in gliomas
    Hai Yan
    Department of Pathology, Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, NC 27710, USA
    N Engl J Med 360:765-73. 2009
    ....
  12. ncbi Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid
    Chunhui Di
    Brain Tumor Center, Department of Pathology, Duke University Medical Center, Research Drive, Durham, NC 27710, USA
    Cancer Res 65:919-24. 2005
    ..These observations suggest that OTX2 is essential for the pathogenesis of anaplastic medulloblastomas and that these tumors may be amenable to therapy with all-trans-retinoic acid...
  13. ncbi IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain
    Giselle Y Lopez
    The Preston Robert Tisch Brain Tumor Center, The Pediatric Brain Tumor Foundation, and the Department of Pathology, Duke University Medical Center, DUMC 3156, Durham, NC 27710, USA
    Biochem Biophys Res Commun 398:585-7. 2010
    ..Studies on the cell-lineages of tumors with IDH1/2 mutations may help clarify the role of these mutations in the development of brain tumors...
  14. ncbi A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation
    Yukinari Kato
    Department of Pathology, Duke University Medical Center, DUMC 3156, Durham, NC 27710, USA
    Biochem Biophys Res Commun 390:547-51. 2009
    ..In conclusion, we established an anti-IDH1(R132H)-specific monoclonal antibody IMab-1, which should be significantly useful for diagnosis and biological evaluation of mutation-bearing gliomas...
  15. ncbi Aberrant otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells
    Matthew Wortham
    Department of Pathology, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 7:e36211. 2012
    ..These studies implicate a role for Otx2 in altering the dynamics of neuronal progenitor cell proliferation...
  16. ncbi Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target
    Changcun Guo
    The Preston Robert Tisch Brain Tumor Center at Duke, Pediatric Brain Tumor Foundation Institute, Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Neurol 24:648-52. 2011
    ..The mechanisms of IDH mutations in gliomagenesis, and their value as diagnostic, prognostic marker and therapeutic target have been extensively studied. This review is to summarize the findings of these studies...
  17. ncbi Digital karyotyping technology: exploring the cancer genome
    Timothy J Parrett
    Department of Pathology, Brain Tumor Center, Duke University Medical Center, 3156, Durham, NC 27710, USA
    Expert Rev Mol Diagn 5:917-25. 2005
    ....
  18. ncbi Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas
    Daniel K Broderick
    Brain Tumor Center, Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 64:5048-50. 2004
    ..These observations implicate PIK3CA as an oncogene in a wider spectrum of adult and pediatric brain tumors and suggest that PIK3CA may be a useful diagnostic marker or a therapeutic target in these cancers...
  19. ncbi Altered telomeres in tumors with ATRX and DAXX mutations
    Christopher M Heaphy
    Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Science 333:425. 2011
    ..ATRX mutations also correlate with abnormal telomeres in tumors of the central nervous system. These data suggest that an alternative telomere maintenance function may operate in human tumors with alterations in the ATRX or DAXX genes...
  20. ncbi IDH1 and IDH2: not your typical oncogenes
    Zachary J Reitman
    The Preston Robert Tisch Brain Tumor Center at Duke, The Pediatric Brain Tumor Institute, and the Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Cell 17:215-6. 2010
    ..However, seemingly oncogenic mutations in IDH1 and IDH2 reduce their native enzyme activity. In this issue of Cancer Cell, Ward et al. pin down a neomorphic enzyme activity as a possible oncogenic function for these alterations...
  21. ncbi Snapshot of the allele-specific variation in human gene expression
    Hai Yan
    Department of Pathology, Duke University Meeical Center, Durham, NC, USA
    Methods Mol Biol 311:31-8. 2005
    ..The studies of allele-specific expression revealed that differential expression is relatively common in the human population...
  22. ncbi Allelic variation in human gene expression
    Hai Yan
    Sidney Kimmel Comprehensive Cancer Center and Howard Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Science 297:1143. 2002
  23. ncbi An integrated genomic analysis of human glioblastoma multiforme
    D Williams Parsons
    Ludwig Center for Cancer Genetics and Therapeutics, and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 321:1807-12. 2008
    ..These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs...
  24. ncbi Allele separation facilitates interpretation of potential splicing alterations and genomic rearrangements
    Hidewaki Nakagawa
    Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 62:4579-82. 2002
    ..These results allowed pathogenicity to be unambiguously assigned to the mutations and increased the sensitivity of genomic testing...
  25. ncbi High frequency of mutations of the PIK3CA gene in human cancers
    Yardena Samuels
    Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Science 304:554. 2004
  26. ncbi Detection of allelic variations of human gene expression by polymerase colonies
    James A Butz
    Department of Chemical Engineering, University of Delaware, Newark, DE 19716, USA
    BMC Genet 5:3. 2004
    ..Herein, we describe the application of an immobilized polymerase chain reaction technique as an alternative approach to measure relative allelic differential expression...
  27. ncbi Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers
    Laura D Wood
    The Ludwig Center for Cancer Genetics and Therapeutics, The Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland 21231, USA
    Hum Mutat 27:1060-1. 2006
    ..Our results implicate these tyrosine kinase genes in the pathogenesis of other tumor types and suggest that they may be useful targets for diagnostic and therapeutic intervention in selected patients...
  28. ncbi Small changes in expression affect predisposition to tumorigenesis
    Hai Yan
    The Howard Hughes Medical Institute, The Oncology Center, and the Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Nat Genet 30:25-6. 2002
    ....